Russo E, Caprnda M, Kruzliak P, Conaldi P G, Borlongan C V, La Rocca G
Section of Histology and Embryology, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Italy.
1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
Stem Cells Int. 2022 Jan 6;2022:2454168. doi: 10.1155/2022/2454168. eCollection 2022.
Chondropathies are increasing worldwide, but effective treatments are currently lacking. Mesenchymal stromal cell (MSCs) transplantation represents a promising approach to counteract the degenerative and inflammatory environment characterizing those pathologies, such as osteoarthritis (OA) and rheumatoid arthritis (RA). Umbilical cord- (UC-) MSCs gained increasing interest due to their multilineage differentiation potential, immunomodulatory, and anti-inflammatory properties as well as higher proliferation rates, abundant supply along with no risks for the donor compared to adult MSCs. In addition, UC-MSCs are physiologically adapted to survive in an ischemic and nutrient-poor environment as well as to produce an extracellular matrix (ECM) similar to that of the cartilage. All these characteristics make UC-MSCs a pivotal source for a stem cell-based treatment of chondropathies. In this review, the regenerative potential of UC-MSCs for the treatment of cartilage diseases will be discussed focusing on in vitro, in vivo, and clinical studies.
软骨病在全球范围内呈上升趋势,但目前缺乏有效的治疗方法。间充质基质细胞(MSCs)移植是一种有前景的方法,可对抗诸如骨关节炎(OA)和类风湿性关节炎(RA)等疾病所特有的退行性和炎症环境。脐带(UC)-间充质干细胞因其多向分化潜能、免疫调节和抗炎特性,以及与成人间充质干细胞相比更高的增殖率、丰富的来源且对供体无风险而受到越来越多的关注。此外,脐带间充质干细胞在生理上适应在缺血和营养匮乏的环境中存活,并产生与软骨相似的细胞外基质(ECM)。所有这些特性使脐带间充质干细胞成为基于干细胞治疗软骨病的关键来源。在本综述中,将重点围绕体外、体内和临床研究,讨论脐带间充质干细胞治疗软骨疾病的再生潜力。